MiR-1236-3p represses the cell migration and invasion abilities by targeting ZEB1 in high-grade serous ovarian carcinoma

Oncology Reports

Volumn 31, Issue 4, 2014, Pages 1905-1910

  Wang, Yu ^a   Yan, Shi ^a   Liu, Xiaolin ^a   Zhang, Wenjing ^a   Li, Yingwei ^a   Dong, Ruifen ^a   Zhang, Qing ^a   Yang, Qifeng ^a   Yuan, Cunzhong ^a   Shen, Keng ^b   Kong, Beihua ^a  

^a SHANDONG UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Epithelial mesenchymal transition; Metastasis; MiR 1236 3p; Ovarian serous carcinoma; Zinc finger E box binding homeobox 1

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 1236 3P; NERVE CELL ADHESION MOLECULE; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UVOMORULIN;

3' UNTRANSLATED REGION; ARTICLE; CANCER CONTROL; CANCER GRADING; CANCER INHIBITION; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CELL STRAIN; CELL STRAIN A2780; CELL STRAIN SKOV3; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; E CADHERIN GENE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS INHIBITION; N CADHERIN GENE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTEIN TARGETING; TISSUE SECTION; UTERINE TUBE;

BLOTTING, WESTERN; CELL MOVEMENT; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MICRORNAS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS;

EID: 84908143877     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3046     Document Type: Article

References (32)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615, 2011.
3. Levanon K, Crum C and Drapkin R: New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26: 5284-5293, 2008.
4. Li J, Fadare O, Xiang L, Kong B and Zheng W: Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J Hematol Oncol 5: 8, 2012.
5. Liu Z, Liu J, Segura MF, et al: MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol 228: 204-215, 2012.
6. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM and Matzuk MM: High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA 109: 3921-3926, 2012.
7. Liu Z, Gersbach E, Zhang X, et al: miR-106a represses the RB tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma. Mol Cancer Res 11: 1314-1325, 2013.
8. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
9. Vergara D, Merlot B, Lucot JP, et al: Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett 291: 59-66, 2010.
10. Berx G, Raspé E, Christofori G, Thiery JP and Sleeman JP: Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis 24: 587-597, 2007.
11. Yang G, Yuan J and Li K: EMT transcription factors: implication in osteosarcoma. Med Oncol 30: 697, 2013.
12. Spaderna S, Schmalhofer O, Wahlbuhl M, et al: The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 68: 537-544, 2008.
13. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233, 2009.
14. Das E, Jana NR and Bhattacharyya NP: MicroRNA-124 targets CCNA2 and regulates cell cycle in STHdhQ111/HdhQ111 cells. Biochem Biophys Res Commun 437: 217-224, 2013.
15. Nakano H, Yamada Y, Miyazawa T and Yoshida T: Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. Int J Oncol 42: 1875-1882, 2013.
16. Icli B, Wara AK, Moslehi J, et al: MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Circ Res 113: 1231-1241, 2013.
17. Calin GA, Dumitru CD, Shimizu M, et al: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524-15529, 2002.
18. Dahiya N and Morin PJ: MicroRNAs in ovarian carcinomas. Endocr Relat Cancer 17: F77-F89, 2010.
19. Bendoraite A, Knouf EC, Garg KS, et al: Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol 116: 117-125, 2010.
20. Chen J, Wang L, Matyunina LV, Hill CG and McDonald JF: Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol 121: 200-205, 2011.
21. Cao M, Seike M, Soeno C, et al: MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. Int J Oncol 41: 869-875, 2012.
22. Ru P, Steele R, Newhall P, Phillips NJ, Toth K and Ray RB: miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol Cancer Ther 11: 1166-1173, 2012.
23. Yokobori T, Suzuki S, Tanaka N, et al: MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci 104: 48-54, 2013.
24. Buys SS, Partridge E, Black A, et al: Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305: 2295-2303, 2011.
25. Sempere LF, Christensen M, Silahtaroglu A, et al: Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67: 11612-11620, 2007.
26. Schaefer A, Jung M, Mollenkopf HJ, et al: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126: 1166-1176, 2010.
27. Sato K, Yoshimura A, Kaneko T, et al: A single nucleotide polymorphism in 3′-untranslated region contributes to the regulation of Toll-like receptor 4 translation. J Biol Chem 287: 25163-25172, 2012.
28. Jones D, Li Y, He Y, Xu Z, Chen H and Min W: Mirtron microRNA-1236 inhibits VEGFR-3 signaling during inflammatory lymphangiogenesis. Arterioscler Thromb Vasc Biol 32: 633-642, 2012.
29. Yokoyama Y, Charnock-Jones DS, Licence D, et al: Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer 88: 237-244, 2003.
30. Kim KH, Jo MS, Suh DS, et al: Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers. World J Surg Oncol 10: 193, 2012.
31. Zhu Y, Huang JM, Zhang GN, Zha X and Deng BF: Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells. J Transl Med 10: 77, 2012.
32. Klasa-Mazurkiewicz D, Jarzab M, Milczek T, Lipińska B and Emerich J: Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients. Pol J Pathol 62: 31-40, 2011.